Study of Sunobinop on Craving in Alcohol Use Disorder

Phase 2

Recruiting

• Conditions: Alcohol Use Disorder
• Interventions: Drug: Sunobinop; Drug: Placebo to match sunobinop

• Registration Number: NCT06545929
• Lead Sponsor: Imbrium Therapeutics

Brief Summary

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-08-06
• Study First Submitted QC: 2024-08-06
• Study First Posted: 2024-08-09
• Study Start: 2025-01-28
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-13
• Primary Completion: 2025-07
• Study Completion: 2025-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sunobinop	Sunobinop	-
Placebo to match sunobinop	Placebo to match sunobinop	-

Primary Outcome Measures

Name	Time	Method
Alcohol Urge Questionnaire (AUQ)	Day 14	The questionnaire consists of 8 items; each with 7-item scale in which 1= "strongly disagree" and 7 = "strongly agree".

Secondary Outcome Measures

Name	Time	Method
Desire for Alcohol Visual Analog Scale (DFA-VAS)	Day 14	The scale consists of 1 item with 10-point scale in which 0 = "not at all" and 10 = "extremely high"

Trial Locations

Locations (1)

Ohio Clinical Trials; 🇺🇸 Columbus, Ohio, United States